Inventiva (NASDAQ:IVA) Issues Earnings Results

Inventiva (NASDAQ:IVA) posted its earnings results on Monday. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.57), FiscalAI reports. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $8.67 million.

Inventiva Stock Performance

NASDAQ IVA traded down $0.24 on Monday, reaching $5.48. The company had a trading volume of 286,516 shares, compared to its average volume of 434,234. Inventiva has a fifty-two week low of $2.85 and a fifty-two week high of $7.98. The business has a 50 day moving average of $6.30 and a two-hundred day moving average of $5.38.

Wall Street Analysts Forecast Growth

IVA has been the topic of several recent research reports. Barclays initiated coverage on Inventiva in a report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. HC Wainwright set a $24.00 target price on Inventiva and gave the company a “buy” rating in a research report on Wednesday, January 28th. Truist Financial began coverage on Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Leerink Partners started coverage on Inventiva in a research note on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Inventiva has an average rating of “Buy” and an average target price of $16.56.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Planning bought a new position in shares of Inventiva during the second quarter worth about $32,000. Millennium Management LLC bought a new stake in Inventiva in the third quarter valued at approximately $649,000. NewEdge Advisors LLC bought a new stake in Inventiva in the third quarter valued at approximately $116,000. Goldman Sachs Group Inc. acquired a new stake in Inventiva during the 4th quarter valued at approximately $1,998,000. Finally, Franklin Resources Inc. acquired a new stake in Inventiva during the 4th quarter valued at approximately $11,626,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.